12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communication to officials on labelling and product monographs.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act: Delays in product approvals and changes to existing products.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.	Legislative Proposal, Bill or Resolution, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.	Legislative Proposal, Bill or Resolution

  Subject matters in previous versions

  • Budget
  • Internal Trade
  • Economic Development
  • Environment
  • Taxation and Finance
  • Industry
  • Intellectual Property
  • Health

Government Institutions

• Global Affairs Canada (GAC)
• Public Health Agency of Canada (PHAC)
• Privy Council Office (PCO)
• Prime Minister's Office (PMO)
• House of Commons
• Finance Canada (FIN)
• Immigration, Refugees and Citizenship Canada (IRCC)
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Health Canada (HC)
• Treasury Board Of Canada Secretariat (TBS)
• Public Services and Procurement Canada (PSPC)
• Senate of Canada

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Oral communication
• Written communication

Senior Officers whose lobbying activities represent less than 20% of their Duties

• James Brodie, General Manager | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Geneviève Lavertu, Director, Government Affairs and Policy – Medical Technology | Public offices held

• Lobbyists in previous versions

  Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

  • Lesia Babiak, Head, Worldwide Government Affairs & Policy (Canada) | No public offices held